Syndicate content

Exosome Diagnostics CEO Presents at Fourth Annual OctoberINVESTfest Event Held at NY Academy of Sciences & Sponsored by Invest in Bavaria; High-Level Conference Connects Investors, Innovators, & Industry Leaders

Exosome Diagnostics, Inc., a developer of what it believes to be revolutionary, biofluid-based molecular diagnostics, announced that Tom McLain, CEO of Exosome Diagnostics, presented, on Tuesday, October 13, 2015, at the Fourth Annual OktoberINVESTfest event (http://www.oktoberinvestfest.com/) at the New York Academy of Sciences in New York City. Mr. McLain’s presentation at this very high-level conference focused on the evolving role of diagnostics in advancing personalized medicine and the progress that Exosome Diagnostics has made in this field. Exosome Diagnostics plans to launch, in 2015, a suite of innovative liquid biopsy tests based on its proprietary, exosome-based ExoLution™ platform to enhance mutation detection, screening, and drug-resistance monitoring for various types of cancer. Exosomes are sub-cellular vesicular messengers released by all living cells into biofluids, such as plasma/serum, urine, cerebrospinal fluid, and saliva. Exosomes can contain RNA, DNA, and proteins from their cell of origin. Exosome Diagnostics’ technology platform can achieve real-time access to comprehensive molecular information about cells in the body without direct access to the actual cells. The company is also exploring the development of exosome-based diagnostics for diseases beyond cancer, including neurodegenerative diseases. OktoberINVESTfest is hosted by Invest in Bavaria (http://www.invest-in-bavaria.com/en.html), the investment and location marketing organization of the German State of Bavaria’s Ministry for Economic Affairs, Media, Energy and Technology. The conference brings together US and German investors, innovators, industry leaders, and Bavarian state representatives, as well as a number of innovative North American and German small and microcap companies and also some early-stage investment opportunities. The resulting business and investment ties will deepen transatlantic relations and encourage economic and scientific exchange. Exosome Diagnostics’ global headquarters and CLIA-certified laboratory are located in Cambridge, Massachusetts, and the company’s European headquarters and research laboratory are located in the Innovation and Startup Center for Biotechnology IZB in Martinsried, Germany.

Exosome Diagnostics

Exosome Diagnostics is a privately held company focused on developing and commercializing what it believes to be revolutionary biofluid-based diagnostics to deliver personalized precision healthcare that improves lives. The company’s novel exosome-based technology platform, ExoLution™, can yield comprehensive and dynamic molecular insights to transform how cancer and other serious diseases are detected, diagnosed, treated and monitored.

Invest in Bavaria

Invest in Bavaria was established in 1999 to serve as the investment promotion agency for the German State of Bavaria by supporting companies from around the world to find ideal locations to set up businesses and/or identify investment opportunities in the state. The organization has played a vital role in connecting US investors and business leaders with Bavaria’s strategic and competitive advantages, in addition to providing them with cost-free, confidential professional services to assist in their investment and site selection process. Additionally, the organization assists Bavarian companies considering international expansion. The Bavarian US offices for Economic Development, LLC, is the representative organization for Invest in Bavaria in the US. There are 26 representative offices of Invest in Bavaria globally, including offices in New York, New Haven, and San Francisco. For additional information, please visit http://www.invest-in-bavaria.com/.

[Press release] [Exosome Diagnostics] [Invest in Bavaria]